araag2/HINT huggingface dataset:
Clinical trial NCT00638963 (phase 2, status: terminated)
Conditions: breast neoplasm, brain neoplasm, second neoplasm
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C71.7, C71.9, C79.31, D33.0, D33.1, D33.2, D49.6, O9A.112, C22.9, C77.0, C77.1, C77.2, C77.3, C77.4
Drugs: temozolomide
SMILES: CSCC[C@H](N)C(O)=O
Reason stopped: 
    terminated due to poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of metastatic breast cancer.

          -  Participants must have completed first line of metastatic chemotherapy and have
             achieved complete or partial response or disease stability for at least 6 months from
             the first confirmation of disease stabilization.

          -  No clinical sign of brain progression.

          -  At least one of the following 3 conditions: HER2 +++, Young age (< 50 years), and/or
             estrogen receptor (ER)-/progesterone receptor (PgR)-

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

          -  Life expectancy ≥3 months.

          -  Neutrophils ≥1.5 x 10^9/L, platelets ≥100 x 10^9/L, hemoglobin ≥9 g/dL, lymphocytes ≥1
             x 10^9/L.

          -  Bilirubin level either normal or <1.5 x ULN (upper limit of normal).

          -  AST (aspartate aminotransferase) and ALT (alanine aminotransferase) ≤2.5 x ULN (≤5 x
             ULN if liver metastases are present).

          -  Serum creatine <1.5 x ULN.

          -  Effective contraception if the risk of conception exists.

        Exclusion Criteria:

          -  Concurrent chronic systemic immune therapy not indicated in the study protocol.

          -  Any investigational agent(s) within 4 weeks prior to entry.

          -  Participants that have completed 2nd, 3rd, or 4th line metastatic chemotherapy or
             participant in active chemotherapy treatment.

          -  Clinically relevant coronary artery disease or a history of a myocardial infarction
             within the last 12 months.

          -  Acute or sub acute intestinal occlusion or history of inflammatory bowel disease.

          -  Known Grade 3 or Grade 4 allergic reaction to any of the components of the treatment.

          -  Known drug abuse/alcohol abuse.

          -  Legal incapacity or limited legal capacity.

          -  Medical or psychological condition which in the opinion of the investigator would not
             permit the participant to complete the study or sign meaningful informed consent.

          -  Women who are pregnant or breastfeeding.

          -  Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of
             the cervix (participants with a previous malignancy but without evidence of disease
             for ≥5 years will be allowed to enter the trial).
Clinical trial NCT01058317 (phase 2/phase 3, status: withdrawn)
Conditions: recurrent respiratory papillomatosis
ICD codes: R09.2, A15.7, A15.8, A15.9, J98.9, R06.03, J12.1
Drugs: propranolol
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Reason stopped: 
    no participants enrolled
  
Eligibility criteria:

        Inclusion Criteria:

          -  1. Biopsy proven with appropriate Human Papilloma Virus typing Recurrent Respiratory
             Papilloma

          -  2. Child under age 10

          -  3. Informed consent and where appropriate informed assent

          -  4. Children who have undergone at least 4 documented surgical interventions in the
             past year.

        Exclusion Criteria:

          -  Parental or child refusal to participate

          -  Heart failure

          -  Atrio-ventricular heart block

          -  Cardiac anomalies

          -  Low resting heart rate

          -  Low resting blood pressure

          -  Wolff-Parkinson White Syndrome

          -  Unexplained syncope

          -  Asthma or Reactive airway disease

          -  Renal or liver failure

          -  Expected long fasting periods, >12 hours

          -  Diabetes Mellitus

          -  Hypersensitivity to propranolol
Clinical trial NCT00481195 (phase 2, status: completed)
Conditions: bipolar i depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: armodafinil, placebo
SMILES: NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  The patient has a diagnosis of Bipolar I Disorder and is currently experiencing a
             major depressive episode.

          -  The patient is currently being treated with 1 or 2 of the following drugs: lithium,
             olanzapine, or valproic acid.

        Key Exclusion Criteria:

          -  The patient has any Axis I disorder apart from Bipolar I Disorder that was the primary
             focus of treatment within 6 months before the screening visit (with the exception of
             nicotine dependence).

          -  The patient has any clinically significant uncontrolled medical or surgical condition.

          -  The patient has previously received modafinil or armodafinil, or the patient has a
             known sensitivity to any ingredients in the study drug tablets.

          -  The patient is a pregnant or lactating woman. (Any woman becoming pregnant during the
             study will be withdrawn from the study.)
Clinical trial NCT01432080 (phase 2, status: terminated)
Conditions: respiratory tract infections, bronchiolitis obliterans, cryptogenic organizing pneumonia, lung diseases, interstitial
ICD codes: J21.9, J84.115, J21.1, J21.0, J21.8, J84.115, J84.170, J84.848
Drugs: prednisone, azithromycin, montelukast, symbicort
SMILES: [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Reason stopped: 
    not meeting recruitment targets
  
Eligibility criteria:

        Inclusion Criteria:

          -  Allogeneic transplant within the prior 1 year

          -  Age greater than or equal to 18 years

          -  Capable of informed consent

          -  Neutrophil engraftment has occurred

          -  This is the first clinically-recognized episode of viral respiratory tract infection
             after transplant

        Exclusion Criteria:

          -  Proof or high suspicion for bacterial, fungal or any non-viral microorganism causing
             pneumonia

          -  CMV, VZV or HSV pneumonia

          -  Prior diagnosis of a chronic transplant-related non-infectious pulmonary complication
             (ex: BO, COP)

          -  Treating physician believes the risk of systemic steroids is too great

          -  Currently receiving prednisone at or greater than 0.25 mg/kg/day or the equivalent
             dose of another steroid

          -  Currently receiving pentostatin

          -  Mycophenolate initiated de novo or increased within the past 4 weeks

          -  Use of inhaled corticosteroids within the past 2 weeks for at least 1 week

          -  Haploidentical or T-cell depleted graft

          -  Lack of pre-transplant pulmonary function tests

          -  Evidence of a prior symptomatic viral respiratory tract infection following
             transplant, whether treated or not

          -  Allergy or adverse reaction to any of the study drugs

          -  Relapse or progression of the underlying malignancy

          -  Palliative care
Clinical trial NCT00396383 (phase 2, status: terminated)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: plerixafor
SMILES: C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1
Reason stopped: 
    insufficient cell mobilization for tandem transplants
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of multiple myeloma (MM)

          -  Eligible for autologous transplantation

          -  Patients in first or second partial remission (PR) or complete remission (CR)

          -  Patients who have received ≦2000 rads of prior radiation therapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Recovered from all acute toxic effects of prior chemotherapy

          -  White blood cells (WBC) >3.0*10^9/l

          -  Absolute polymorphonuclear leucocyte (PMN) count >1.5*10^9/l

          -  Platelet (PLT) count > 150*10^9/l

          -  Serum creatinine ≦2.2 mg/dl

          -  Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase
             (SGPT) and total bilirubin <2 x upper limit of normal (ULN)

          -  Negative for HIV

          -  Signed informed consent

          -  Patients of childbearing potential agree to use an approved form of contraception

        Exclusion Criteria:

          -  Patient received 2 or more alkylating agents, such as VBMCP (a combination of
             Vincristine, BCNU (Bis-Chloronitrosourea), Melphalan, Cyclophosphamide, and
             Prednisone)

          -  Patient received a total dose of ≧200 mg of prior melphalan

          -  A co-morbid condition which, in the view of the investigators, renders the patient at
             high risk from treatment complications

          -  Patient has failed previous collections or collection attempts

          -  A residual acute medical condition resulting from prior chemotherapy

          -  Brain metastases or carcinomatous meningitis

          -  Acute infection

          -  Fever (temperature >38 °C / 100.4 °F)

          -  Hypercalcemia (>1mg/dl above ULN)

          -  Positive pregnancy test in female patients

          -  Lactating females

          -  Patients of childbearing potential unwilling to implement adequate birth control

          -  Patients whose actual body weight exceeds 175% of their ideal body weight

          -  History of ventricular arrhythmias

          -  Patient received thalidomide within 10 days prior to receiving the first dose of
             plerixafor

          -  Patients who previously received experimental therapy within 4 weeks of enrolling in
             this protocol or who are currently enrolled in another experimental protocol during
             the mobilization phase
Clinical trial NCT00308529 (phase 2, status: completed)
Conditions: carcinoma, small cell lung, lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: irinotecan, carboplatin, bevacizumab
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O, N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically-confirmed small cell lung cancer.

          -  Limited stage disease (

          -  ECOG performance status 0 or 1.

          -  No previous treatment with chemotherapy, radiation therapy, or biologic agents.

          -  Measurable disease

          -  Adequate bone marrow, liver, kidney function

          -  Patients must be able to understand the nature of this study and give written consent.

        Exclusion Criteria:

          -  Age < 18 years

          -  History of a prior malignancy within three years with the exception of skin cancer
             (excluding melanoma), cervical carcinoma in situ, in situ breast carcinoma, or early
             stage prostate cancer.

          -  Women who are pregnant or lactating are ineligible. Men and women of childbearing
             potential are required to use adequate contraception during this study.

          -  History or physical exam evidence of CNS disease (eg seizures not controlled with
             standard medical therapy, history of stroke)

          -  Active infection requiring parenteral antibiotics

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 0, or fine needle aspiration within 7 days of beginning bevacizumab or
             anticipation of need for major surgical procedure during the course of the study.

          -  Full-dose oral or parenteral anticoagulation must be on a stable dosing schedule prior
             to enrollment.

          -  Proteinuria

          -  Serious nonhealing wound, ulcer, or bone fracture

          -  Evidence of bleeding diathesis or coagulopathy

          -  Prior hemoptysis.

          -  History of acute myocardial infarction or stroke within 6 months

          -  Uncontrolled hypertension (> 150/100), unstable angina, New York Heart Association
             grade II or greater CHF, serious cardiac arrhythmia requiring medication, or grade II
             or greater peripheral vascular disease.

          -  Received other investigational drugs within 28 days

          -  PEG, G-tubes, or other percutaneous drains/tubes

          -  History of any other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates use of an investigational drug or that might affect interpretation of
             the results of the study or place the subject at high risk for treatment complications

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within the previous 6 months
Clinical trial NCT00475319 (phase 2, status: completed)
Conditions: dry eye syndromes
ICD codes: H04.121, H04.122, H04.123, H04.129
Drugs: placebo, 1% opc-12759 ophthalmic suspension, 2% opc-12759 ophthalmic suspension
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OC(=O)C(CC1=CC(O)=NC2=CC=CC=C12)NC(=O)C1=CC=C(Cl)C=C1, OC(=O)C(CC1=CC(O)=NC2=CC=CC=C12)NC(=O)C1=CC=C(Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Outpatient

          2. Subjective complaint of dry eye that has been present for minimum 20 months

          3. Ocular discomfort severity is moderate to severe

          4. Corneal - conjunctival damage is moderate to severe

          5. Unanesthetized Schirmer's test score of 5mm/5minutes or less

          6. Best corrected visual acuity of 0.2 or better in both eyes

        Exclusion Criteria:

          1. Presence of anterior segment disease or disorder other than that associated with
             keratoconjunctivitis sicca

          2. Ocular hypertension patient or glaucoma patient with ophthalmic solution

          3. Anticipated use of any topically-instilled ocular medications or patients who cannot
             discontinue the use during the study

          4. Anticipated use of contact lens during the study

          5. Patient with punctal plug

          6. Any history of ocular surgery within 12 months

          7. Female patients who are pregnant, possibly pregnant or breast feeding

          8. Known hypersensitivity to any component of the study drug or procedural medications

          9. Receipt of any investigational product within 4 months
Clinical trial NCT00698451 (phase 2, status: completed)
Conditions: ovarian neoplasms, fallopian tube neoplasms, peritoneal neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C57.00, C57.01, C57.02, K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02
Drugs: doxorubicin hcl liposome; bevacizumab; carboplatin
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic diagnosis of epithelial ovarian, fallopian tube or primary peritoneal
             cancer

          -  Relapse-free interval of >6 months afer completion of first line platinum-based
             chemotherapy

          -  Measurable disease (at least one lesion that can be accurately measured in a least 1
             dimension)

          -  Adequate bone marrow function, renal, and liver function. Normal cardiac function

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

        Exclusion Criteria:

          -  No patients who have received more than 1 previous regimen of chemotherapy
             (maintenance is not considered a second regimen)

          -  No patients receiving immunotherapy or radiotherapy or patients who have received
             prior radiotherapy to any portion of the abdominal cavity or pelvis

          -  No patients who require parenteral hydration or nutrition or have clinical signs or
             symptoms of gastrointestinal bowel obstruction or perforation

          -  No patients with previous or current malignancy other than basal cell or squamous cell
             carcinoma of the skin

          -  No patients with clinically significant cardiovascular disease

          -  No patients with a history of bevacizumab or other VEGF or VEGF receptor-targeted
             agent use.
Clinical trial NCT00525408 (phase 2, status: terminated)
Conditions: hormone refractory prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    interim analysis report indicates trial futility
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate with clinical
             or radiologic evidence of metastatic disease.

          -  Disease progression during antiandrogen therapy, having surgical or medical castration
             status.

          -  Karnofsky Performance Status 50-100

          -  Normal cardiac function

          -  Life expectancy at least 24 weeks.

          -  Laboratory criteria for eligibility will include

          -  A neutrophil count of at least 1500 per cubic millimeter

          -  A hemoglobin level of at least 9 gm%

          -  A platelet count of at least 1000,000 per cubic millimeter.

          -  A total bilirubin not grater than 1.5 times the upper limit of the normal range for
             each institution.

          -  Serum creatinine levels not more than 1.5 times the upper limit of the normal range

          -  Written informed consent

        Exclusion Criteria:

          -  Prior treatment with cytotoxic agents or radioisotopes

          -  Estrogen use for at least three months

          -  History of another cancer within the preceding five years (except basal or
             squamous-cell skin cancer)

          -  Brain or leptomeningeal metastases

          -  Symptomatic peripheral neuropathy of grade 2 or higher

          -  Uncontrolled intercurrent illness that would limit compliance with study requirements
Clinical trial NCT00289952 (phase 2, status: unknown status)
Conditions: hiv infections
ICD codes: Z21
Drugs: valproic acid, haart
SMILES: [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O, [H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[C@H](C)CCO2
Eligibility criteria:

        Inclusion Criteria:

        Documented HIV seropositive infection by Western Blot, EIA assays or viral load.

          -  Aged 18 years old or older.

          -  Viral load <50 copies/ml for at least the previous 12 months.

          -  Circulating CD4+ cell count ³ 200 cells/ml.

          -  Taking HAART.

          -  Vital signs, physical examination and laboratory results do not exhibit evidence of
             diseases such as advanced cirrhosis and advanced liver disease (ALT or AST > 5 x upper
             limit of normal value).

          -  Karnofsky performance status 80%.

          -  Subject does not require and agrees not to take, for the duration of the study, any
             medication that is contraindicated with VPA.

          -  Willing and able to give informed consent.

          -  All participants will agree to abstinence or to used effective methods of
             contraception while on the study.

        Exclusion Criteria:

          -  Pregnant or breast-feeding women.

          -  Psychiatric or cognitive disturbance or illness that could preclude compliance with
             the study.

          -  Current use or use within four weeks prior to the baseline visit, of cytotoxic agents,
             systemic corticosteroids or any immunomodulatory agents such as intravenous
             immunoglobulin, or hydroxyurea.

          -  HIV vaccine within six months of screening visit

          -  Allergic reaction to VPA.

          -  Active intravenous drug users.

          -  History of bleeding disorders.

          -  Unstable or treated hypertension.

          -  Past-history of pancreatitis or chronic liver disease (ALT or AST > 5 x upper limit of
             normal value). However subject co-infected with hepatitis B or C can participate if
             ALT or AST is < 5 x upper limit of normal value.

          -  Renal failure (creatinine > 2 x upper limit of normal value).

          -  Ammonemia (> 2x upper limit of normal value).

          -  Taking Zidovudine (AZT), or combination of drugs containing AZT like Combivir or
             Trizivir. However this subject will be asked to switch to another NRTI,at least two
             weeks prior to Valproic Acid initiation, to become eligible.

          -  Taking on daily basis: phenytoin, carbamazepine, phenobarbital, warfarin or aspirin.

          -  Subject has any of the following abnormal laboratory results Hemoglobin < 100 g/L.
             Absolute neutrophil count < 0.75 x 10 9 cells/L. Platelet count < 50 x 10 9 cells/L.

          -  Subject suffering from urea cycle disorders.
Clinical trial NCT00460811 (phase 2, status: completed)
Conditions: irritable bowel syndrome with constipation
ICD codes: K58.1
Drugs: linaclotide acetate, matching placebo
SMILES: [H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Must not be pregnant or breastfeeding and agree to use birth control;

          -  Completion of a negative colonoscopy as per American Gastroenterology Association
             (AGA) criteria and no clinically-significant laboratory or physical examination
             findings;

          -  Meets protocol-defined criteria for IBS-C, including stool frequency, straining, stool
             consistency, abdominal pain, and abdominal discomfort criteria;

          -  Demonstrates English fluency and has access to a touch-tone telephone.

        Exclusion Criteria:

          -  Recent history of mushy or watery stools;

          -  Various medical conditions, medical histories, or family medical histories that would
             not make the patient a good candidate for the study;

          -  Clinically-significant alarm symptoms;

          -  Secondary causes of constipation or evacuation disorders;

          -  Surgery to the gastrointestinal tract;

          -  Usage of prohibited medications.